Concerto HealthAI has an exclusive, 10-year license with ASCO’s CancerLinQ. Our collective RWD solutions now have over 1.5M patient records, with scheduled future growth.

Our RWD support key research programs of ASCO and the FDA, advancing the industry’s confidence in and expanding the use cases of real-world evidence.

Presentations at 2019 ASCO Annual Meeting Utilizing CancerLinQ Derived Analyses: FDA Collaboration